0001209191-22-034043.txt : 20220603 0001209191-22-034043.hdr.sgml : 20220603 20220603162523 ACCESSION NUMBER: 0001209191-22-034043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220601 FILED AS OF DATE: 20220603 DATE AS OF CHANGE: 20220603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORDON CARL L CENTRAL INDEX KEY: 0001282930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 22994820 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-513-8774 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-01 0 0001664710 Keros Therapeutics, Inc. KROS 0001282930 GORDON CARL L C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421 1 0 0 0 Stock Options (right to buy) 32.95 2022-06-01 4 A 0 8293 0.00 A 2032-05-31 Common Stock 8293 8293 D The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP. /s/ Keith Regnante, Attorney-in-Fact 2022-06-03